Some error occured while loading the Quick View. Please close the Quick View and try reloading the page.
Cancer Pharmacology and Pharmacotherapy Reviewis the first book devoted entirely to providing the "must-know" facts on each cancer agent, including their pharmacokinetics, FDA-approved indications,toxicity, interactions, and other important information that is commonly found on board examinations and essential for any clinician or practitioner to review. The authors, an oncologist and two pharmacists, have developed a handy question-and-answer format to present the material in digestible bursts.
As the pharmacology section continues to represent a major portion of the medical oncology exam and a key component on oncology MOC exams, this portable study guide will help prepare anyone looking to fine-tune their knowledge on cancer drugs before the test. Not to mention, with recent advancements in the field of cancer treatment, it has become more cumbersome to recall and maintain essential knowledge of every cancer therapeutic, making this book not only an exam resource but also a handy quick reference for oncologists and pharmacists alike.
KEY FEATURES
- Conveniently organized and arranged by drug class and subtypes for easier recall and classification
- Includes proper dosage adjustments to account for liver and kidney dysfunction
- Features tables throughout that provide quick reference regarding FDA-approved medications
- Simplified diagrams and illustrations facilitate the pharmacokinetic processes
Contents
List of Figures
List of Tables
Preface
I. Traditional Chemotherapy
1. Microtubule Inhibitors
Taxanes and Related Agents
Vinca Alkaloids
2. Alkylating Agents
Nitrogen Mustards
Non-Nitrogen Mustards
Platinums
Antitumor Antibiotics
3. Enzyme Inhibitors—Topoisomerase I Inhibitors
Camptothecans
4. Enzyme Inhibitors—Topoisomerase II Inhibitors
Epipodophyllotoxins
Anthracyclines
5. Antimetabolites
Antifolates
Purine Antagonists
Purine Analogues
Pyrimidine Analogues/Fluoropyrimidines
Pyrimidine Analogues/Deoxycytidine Analogues
II. Next-Generation Antineoplastics
6. Monoclonal Antibodies
7. VEGF Trap
Ziv-Aflibercept (Zaltrap®)
8. Tyrosine Kinase Inhibitors
Angiogenesis Inhibitors and Multi-Kinase Inhibitors
Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-ABL) Inhibitors
B-Cell Receptor (BCR) Pathway Inhibitors
EGFR-Ras-Raf-MEK-ERK (MAPK) Pathway Inhibitors
Miscellaneous Oral Targeted Therapies
9. Antiandrogen Therapies
10. Mammalian Target of Rapamycin (mTOR) Inhibitors
11. Histone Deacetylase (HDAC) Inhibitors
12. Hypomethylating Agents
13. Proteasome Inhibitors
14. Immunomodulatory Agents
15. L-Asparaginase Enzymes
16. Promyelocytic Leukemia Gene Retinoic Acid Receptor-Alpha (PML-RARα) Translocation Inhibitors
III. Miscellaneous Oncolytics
17. Sipuleucel-T (Provenge®)
18. Omacetaxine (Synribo®)
19. Estramustine (Emcyt®)
Appendix A: Agents Requiring Renal and/or Hepatic Dose Adjustments
Appendix B: Extravasation Risk of Chemotherapeutic Agents
Index